Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Poster entitled, ”Preclinical Studies of SB 9200 for Hepatitis Treatment” will be presented by Marci Harter of MPI Research at the upcoming American College of Toxicology’s 34th Annual Meeting

Milford, MA.  A Poster entitled, ”Preclinical Studies of SB 9200 for Hepatitis Treatment” will be presented by Marci Harter of MPI Research at the upcoming American College of Toxicology’s 34th Annual Meeting, in San Antonio, Texas. The presentation will include IND-enabling preclinical toxicology and safety pharmacology studies of SB 9200, an investigational drug candidate against HBV and HCV.

SB 9200 is currently in Phase I clinical trials and is being evaluated in healthy, HCV-infected patients.